CRISPR Probability Of Bankruptcy

CRSP
 Stock
  

USD 80.14  1.48  1.88%   

CRISPR Therapeutics Probability Of Bankruptcy is used to show its chance of financial distress over the next two years of operations under current economic and market conditions. CRISPR Therapeutics Probability Of Bankruptcy is determined by interpolating and adjusting CRISPR Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the CRISPR balance sheet as well as cash flow and income statements available from the company's most recent filings. Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis.
  
CRISPR Therapeutics Invested Capital Average is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Invested Capital Average of 1.48 Billion. As of 15th of August 2022, Tangible Asset Value is likely to grow to about 3 B, while Enterprise Value is likely to drop about 4.5 B.

CRISPR Probability Of Bankruptcy Analysis

CRISPR Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
 2021 2022 (projected)
Interest Expense9.26 M9.99 M
Gross Profit914.96 M987.2 M
Probability Of Bankruptcy 
 = 
Normalized 
 
Z-Score 
More About Probability Of Bankruptcy | All Equity Analysis

Current CRISPR Therapeutics Probability Of Bankruptcy

    
  1%  
Most of CRISPR Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CRISPR Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of CRISPR Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting CRISPR Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of CRISPR Therapeutics AG financial health.
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.1 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

CRISPR Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for CRISPR Therapeutics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since CRISPR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CRISPR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CRISPR Therapeutics' interrelated accounts and indicators.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Compare to competition

Based on the latest financial disclosure, CRISPR Therapeutics AG has a Probability Of Bankruptcy of 1.0%. This is 97.69% lower than that of the Healthcare sector and 98.18% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 97.49% higher than that of the company.

CRISPR Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CRISPR Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CRISPR Therapeutics could also be used in its relative valuation, which is a method of valuing CRISPR Therapeutics by comparing valuation metrics of similar companies.
CRISPR Therapeutics is currently under evaluation in probability of bankruptcy category among related companies.

CRISPR Therapeutics Main Bankruptcy Drivers

201720182019202020212022 (projected)
Return on Average Assets(0.23)(0.38)0.096(0.26)0.140.16
Asset Turnover0.140.0070.420.0010.350.38
Total Liabilities83.51 M96.82 M127.33 M163.73 M352.42 M380.24 M
Current Liabilities14.51 M27.75 M57.11 M94.26 M119.88 M129.35 M
Total Assets271.35 M489.02 M1.07 B1.83 B2.75 B2.97 B
Current Assets248.38 M466.39 M987.55 M1.72 B2.42 B2.61 B
Net Cash Flow from Operations(70.09 M)(96.24 M)56.68 M(238.37 M)538.97 M581.52 M
Weighted Average Shares40.06 M47.96 M54.39 M65.95 M75.95 M62.06 M
Weighted Average Shares Diluted40.06 M47.96 M56.93 M65.95 M80.39 M64.9 M

CRISPR Fundamentals

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against CRISPR Therapeutics

0.81ABVCAbvc Biopharma Earnings Call  TodayPairCorr
0.76ALRNAileron Therapeutics Earnings Call  TodayPairCorr
0.72ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.65AGTCApplied Genetic Tech Fiscal Year End 22nd of September 2022 PairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.1 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.